Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia

Pfizer

Status and phase

Completed

Phase 3

Conditions

Community-Acquired Pneumonia

Treatments

Drug: Azithromycin microspheres 2.0 single dose

Study type

Interventional

Funder types

Industry

Identifiers

NCT00140023

A0661149

Details and patient eligibility

About

The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response. All subjects who receive 1 dose of study medication will be assessed for safety.

Enrollment

47 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, 18 years age or older, for whom oral, outpatient therapy is indicated.
Diagnosis of CAP as manifested by at least 3 or more of the following:
cough, pleuritic chest pain, fever (temperature of >37.8 C to <40 C), auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation, dyspnea, tachypnea, laboratory results of elevated total peripheral white blood count (WBC> 10,000/mm3 or greater than 15% immature neutrophils (bands)

Exclusion criteria

Known or suspected hypersensitivity or intolerance to azithromycin or other macrolides.
Previously diagnosed disease(s) of immune function, including: subjects with baseline absolute neutrophil count < 1,000/mm3, HIV positive subjects with CD4 count < 200 cells/mm3, any immunoglobin or neutrophil disorder.